How Long Can You Safely Stay on Cosentyx?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions, has safety data from clinical trials and real-world use supporting continuous treatment beyond 5 years for many patients. No fixed upper limit exists; safety is assessed individually based on response, side effects, and monitoring.[1]
What Clinical Trials Show for Long-Term Use
Phase 3 trials like FUTURE and MEASURE tracked patients up to 5 years. In psoriasis studies, 78-85% maintained PASI 75 response at year 5 with 300 mg dosing, with consistent safety—no new risks emerged over time. Exposure-adjusted infection rates stayed stable (around 1.2 events per patient-year), and serious infections were rare (0.7%). Antidrug antibodies developed in <1%, rarely impacting efficacy.[2][3]
In ankylosing spondylitis (MEASURE), 80% retained ASAS 20 response at 5 years, with malignancy rates comparable to placebo (0.4%). Long-term extensions confirm no cumulative toxicity signals.[1]
Real-World Data on Years of Continuous Use
Post-approval registries like SCULPTURE (up to 7 years) and CorEvitas (U.S., >3 years average) report similar profiles: persistence rates of 60-70% at 3 years, dropping due to inefficacy rather than safety. Serious adverse events occur at 4-6% annually, mostly infections or flares, not worsening with duration.[4]
No evidence of organ damage or increased cancer risk with extended use in population studies up to 8+ years.[1]
Common Risks and When to Stop
Infections (upper respiratory, candida) are most frequent (43% over 5 years), but severe cases are low (1-2%). Monitor for tuberculosis reactivation pre-start and annually. Inflammatory bowel disease risk (0.1-0.4%) may prompt discontinuation. Guidelines recommend staying on if benefits outweigh risks, with annual labs for liver/kidney function and blood counts.[5]
Discontinue if no response after 3-6 months, serious infection, or malignancy develops. Pregnancy requires stopping 5 half-lives prior (about 5 weeks).[1]
Who Makes Cosentyx and Patent Timeline
Novartis manufactures Cosentyx. U.S. patents expire around 2033-2034, with pediatric exclusivity to 2035; biosimilars unlikely before then, barring challenges.[6] For updates, check DrugPatentWatch.com.
Sources:
[1] Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2] Bissonnette et al., J Am Acad Dermatol, 2018.
[3] Baeten et al., Ann Rheum Dis, 2018.
[4] Papp et al., J Eur Acad Dermatol Venereol, 2021.
[5] American College of Rheumatology Guidelines, 2021.
[6] DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/COSENTYX